CROs working on Antibody-Drug Conjugate (ADC)
Antibody-Drug Conjugate (ADC) is an important modality used by sponsors to shortlist partners for specific delivery, regulatory, and execution needs. This page groups CRO organizations working on Antibody-Drug Conjugate (ADC), so you can quickly identify which teams align with your program priorities without having to scan unrelated profiles.
Use this listing as a starting point: open each profile to review scope, facility footprint, and public evidence that supports the listed capabilities. Because the directory is fit-first, the goal is not to crown one universal "best" provider, but to help you build a right-sized shortlist for your stage, geography, and quality expectations.
When you are ready to compare options, move to search and add filters for adjacent criteria such as modalities, indications, and claim status. Combining this modality view with those filters makes it easier to narrow quickly from discovery to outreach while keeping the process transparent and reproducible.
Auto-generated by BioBM Editorial AI.
Matching companies
- Aliri Bioanalysis
Bioanalytical CRO specializing in PK/PD, biomarker, and spatial imaging services across discovery through Phase 3 clinical trials, with 20+ years of regulatory expertise.
- Allucent
Allucent is a full-service CRO specializing in clinical development solutions for small and mid-sized biotech companies. With over 30 years of background in regulatory trends, therapeutic experience, and operational expertise, the company partners with biopharma to advance…
- Aragen Life Sciences
Global CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
- BioDuro-Sundia
Integrated CRDMO with 30 years of expertise spanning discovery chemistry, biology, DMPK, and IND-enabling development for small and large molecules, plus API and drug product manufacturing.
- Celerion
Global CRO specializing in early-phase clinical research and bioanalytical sciences with 650+ beds across 30 countries and 50+ years of experience.
- Certara
Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
- Champions Oncology
Leading oncology CRO specializing in preclinical and clinical specialty testing, with over 1,400 patient-derived xenograft models, comprehensive multi-omic datasets, and proprietary platforms including flow cytometry, NGS, proteomics, and histopathology services.
- ChemPartner
Global preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.
- Crown Bioscience
Preclinical oncology CRO offering 2,500+ PDX models, organoid and cell line databases, and translational platforms with biomarker discovery and AI-driven systems biology for drug development.
- Frontage Laboratories
Global pharmaceutical development organization offering integrated drug discovery, preclinical safety/toxicology, DMPK, bioanalytical, and clinical trial services across 28 sites with 2,200 employees and 200+ FDA inspections.
- KCAS Bio
Leading bioanalytical CRO with 45+ years of experience, supporting 315+ approved drugs through bioanalysis, biomarker, immunogenicity, flow cytometry, and clinical kitting services across US, EU, and Australia facilities.
- Oncodesign Services
Contract research organization specializing in drug discovery and preclinical services for oncology, inflammation, and infectious diseases since 1995.
- Pharmaron
Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- Reaction Biology
Global preclinical CRO specializing in kinase drug discovery, cell-based assays, in vivo pharmacology, and immuno-oncology with 1,000+ cell lines and hundreds of validated protein targets across US and EU facilities.
- Syngene International
Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
- Worldwide Clinical Trials
Full-service global CRO with 30+ years of therapeutic expertise, delivering personalized clinical trial support across rare disease, cardiovascular, cell & gene therapy, oncology, and neuroscience.
- WuXi AppTec
Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /modalities/mod_adc.md